Chargement en cours...
Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
Myelodysplastic syndromes (MDS) are a spectrum of clonal stem-cell disorders characterized clinically by bone-marrow failure. Resultant cytopenias are responsible for significant mortality and decreased quality of life in patients with MDS. In patients with low-risk MDS (LR-MDS), anemia is the most...
Enregistré dans:
| Publié dans: | Ther Adv Hematol |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE Publications
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7812395/ https://ncbi.nlm.nih.gov/pubmed/33505645 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620720986641 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|